Summary
The EORTC Urological Group is one of the 31 clinical groups and working parties within the European Organization for Research and Treatment of Cancer (EORTC). Intravesical chemotherapy has been used as chemoresection or chemoprophylaxis. Chemoresection has mainly been utilized in phase II studies to demonstrate ablation of existing disease and to study the mechanism of drug action. These studies are usually performed by individual members to obtain relevants information for the preparation of randomized trials. One example is a phase II chemoresection study with 4′-epi-doxorubicin (ERP). The EORTC GU Group extended its phase II trials to study remission in patients with primary carcinoma in situ. A new concept introduced in the prospective, randomized phase III trials includes the evaluation of chemoresection of a marker lesion as a prognostic factor in long-term prophylactic treatment. Chemoprophylaxis in the phase III trials aims to study the disease-free period, the recurrence rate and the long-term survival. So far, a series of five phase III trials, totaling more than 2,000 patients, demonstrated the efficacy of chemoprophylaxis to reduce tumor recurrence rates. The variation in the results of the different trials are due more to the prognostic factors (characteristics of the tumors) than to the related efficacy of the chemoprophylactic drugs. The selection of currently employed drugs, Mitomycin C, Epirubicin and BCG, is based on reported results, lack of toxicity, and drug availability in Europe. The data collected will be of great importance to determine the optimal clinical management of superficial bladder cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bouffioux C, Denis L, Bultinck J, Bono A, Bollack C, Calais da Silva F (1986) Epirubicin: a phase II chemoresection study. Abstract Book, 7th Congress of the European Association of Urology, Budapest, abstract no. 2232: 353
Brosman SA (1985) The use of bacillus Calmette-Guérin in the therapy of bladder carcinoma in situ. J Urol 134: 36
Cant JD, Murphy WM, Soloway MS (1986) Prognostic significance of urine cytology on initial follow-up after intravesical mitomycin C for superficial bladder cancer. Cancer 57: 2119–2122
Dalesio O, Schulman C, Sylvester R, De Pauw M, Robinson M, Denis L, Smith P, Viggiano G, Memberns of the Genito-Urinary Tract Cooperative Group (1983) Prognostic factors in superficial bladder tumors: a study of the EORTC Genito-Urinary Tract Cooperative Group. J Urol 129: 730–733
de Kernion JB, Huang M, Lindner A, Smith RB, Kaufman JJ (1985) The management of superficial bladder tumors and carcinoma in situ with intravesical bacillus Calmette Guérin. J Urol 133: 598
de la Pena J, Martinez-Pineiro JA, Hidalgo L, Perdices C (1986) A randomized study comparing intravesical BCG, ADM and TTPA. Second report. Abstract Book, 7th Congress of the European Association of Urology, Budapest, abstract no. 2204: 338
Denis L (1983) Anaphylactic reaction to repeated intravesical instillation cisplatin. Lancet I: 1378
Denis L, Keuppens F, Hendrickx G (1985) Mitomycin C in superficial bladder cancer. In: Schröder F, Richards B (eds) EORTC GU Group Monograph 2, part B: superficial bladder tumors. Alan R Liss, New York, pp 113–122
Denis L, Niijima T, Prout GRjr, Schröder F (1987) Consensus development in bladder cancer. Guidelines for clinical research. EORTC GU Group Monograph Series in Clinical and Biological Research. Alan R Liss, New York (in press)
Fossa SD, Miller A, Stenwig AE (1983) Intravesical thiotepa prophylaxis of superficial bladder cancer: a follow-up study. Eur Urol 9: 307–210
Friedell GH, Soloway MS, Hilgar AG, Farrow GM (1986) Summary of workshop on carcinoma in situ of the bladder. J Urol 136 (in press)
Green DF, Robinson MRG, Glashan R, Newling D, Dalesio O, Smith PH (1984) Does intravesical chemotherapy prevent invasive bladder cancer? J Urol 131: 33–35
Herring H (1938) The treatment of vesical papilloma by injections. Br Med J 2: 16
Huland U, Otto U, Droese M, Klöppel G (1984) Long term mitomycin C instillation after transurethral resection of superficial bladder carcinoma: influence on recurrence, progression and survival. J Urol 132: 27
Jones H, Swinney J (1961) Thiotepa in the treatment of tumors of the bladder. Lancet II: 615
Kurth KH, Debruyne F, Senge T, Carpentier P, Riedl H, Sylvester R, De Pauw M, EORTC GU Group (1985) Ajuvant chemotherapy for transitional superficial cell carcinoma of the bladder: an EORTC randomized study comparing doxorubicin hydrochloride, ethoglucid and TUR alone. In: Schröder F, Richards B (eds) EORTC GU Group Monograph 2, part B: Superficial bladder tumors. Alan R Liss, New York, p 135
Nakada T, Akiya T, Yoshikawa M, Koike H, Kayayama T (1985) Intravescial instillation of doxorubicin hydrochloride and its incorporation into bladder tumors. J Urol 134: 54–56
Niijima T, Koiso K, Akaza H (1983) Randomized clinical trial on chemoprophylaxis of recurrence in cases of superficial bladder cancer. Cancer Chemother Pharmacol [Suppl] 11: 579–582
Pavone-Macaluso M, Pavone C, Cacciatore M, Ingargiola GB (1985) Intravesical adriamycin. In: Schröder F, Richards B (eds) EORTC GU Group Monography 2, part B: Superficial bladder tumors. Alan R Liss. New York pp 123–133
Prout GR, Koontz WW, Coombs LJ, Hawkins IR, Friedell GH (1983) Long term fate of 90 patients with superficial bladder cancer randomly assigned to receive or not to receive thiotepa. J Urol 83: 677–680
Ruttac RWTH Aachen, Fischer N, Rübben H, Lutzeyer W (1986) Intravesikale chemorezidivprophylaxe superfizialer blasenkarzinome mit Adriamycin. Verh Dtsch Ges Urol 9
Schulman C, Robinson M, Denis L, Smith P, Viggiano G, De Pauw M, Dalesio O, Sylvester R, Members of the EORTC Genito-Urinary Tract Cancer Cooperative Group (1982) Prophylactic chemotherapy of superficial transitional cell bladder carcinoma: an EORTC randomized trial comparing thiotepa, an epipodophyllotoxin (VM 26) and TUR alone. Eur Urol 8: 207–212
Viggiano G, Denis L, Bouffioux C, Oosterlinck W, De Pauw M, EORTC Urological Group (1985) Phase III intravesical chemotherapy with thiotepa, adriamycin and cisplatinum for recurrent Tl carcinoma of the bladder. Abstract Book, XX Congress of the International Society of Urology, Vienna, p 190
Author information
Authors and Affiliations
Consortia
Rights and permissions
About this article
Cite this article
Denis, L., Bouffioux, C., Kurth, K.H. et al. Current status of intravesical chemotherapy trials in the EORTC Urological Group. An Overview. Cancer Chemother. Pharmacol. 20 (Suppl 1), S67–S71 (1987). https://doi.org/10.1007/BF00262490
Issue Date:
DOI: https://doi.org/10.1007/BF00262490